Sato, A. Y. et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost/sclerostin. J. Bone Miner. Res. 31, 1791–1802 (2016).
Article CAS PubMed Google Scholar
Modder, U. I. et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J. Bone Miner. Res. 26, 373–379 (2010).
Article PubMed Central Google Scholar
Mirza, F. S., Padhi, I. D., Raisz, L. G. & Lorenzo, J. A. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J. Clin. Endocrinol. Metab. 95, 1991–1997 (2010).
Article PubMed PubMed Central Google Scholar
Leanza, G. et al. Bone canonical Wnt signaling is downregulated in type 2 diabetes and associates with higher advanced glycation end-products (AGEs) content and reduced bone strength. eLife 12, RP90437 (2024).
Article PubMed PubMed Central Google Scholar
Maycas, M. et al. PTHrP-derived peptides restore bone mass and strength in diabetic mice: additive effect of mechanical loading. J. Bone Min. Res. 32, 486–497 (2017).
Garcia-Martin, A. et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 97, 234–241 (2012).
Article CAS PubMed Google Scholar
Yamamoto, M., Yamauchi, M. & Sugimoto, T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 98, 4030–4037 (2013).
Article CAS PubMed Google Scholar
Dragoun Kolibová, S. et al. Osteocyte apoptosis and cellular micropetrosis signify skeletal aging in type 1 diabetes. Acta Biomater. 162, 254–265 (2023).
Shao, X. et al. Amelioration of bone fragility by pulsed electromagnetic fields in type 2 diabetic KK-Ay mice involving Wnt/β-catenin signaling. Am. J. Physiol. Endocrinol. Metab. 320, E951–E966 (2021).
Article CAS PubMed Google Scholar
Abou-Samra, A. B. et al. Structure, function, and expression of the receptor for parathyroid hormone and parathyroid hormone-related peptide. Adv. Nephrol. Necker Hosp. 23, 247–264 (1994).
Lanske, B. et al. The parathyroid hormone (PTH)/PTH-related peptide receptor mediates actions of both ligands in murine bone. Endocrinology 139, 5194–5204 (1998).
Article CAS PubMed Google Scholar
Sutkeviciute, I., Clark, L. J., White, A. D., Gardella, T. J. & Vilardaga, J.-P. PTH/PTHrP receptor signaling, allostery, and structures. Trends Endocrinol. Metab. 30, 860–874 (2019).
Article CAS PubMed PubMed Central Google Scholar
Dean, T., Vilardaga, J. P., Potts, J. T. Jr. & Gardella, T. J. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol. Endocrinol. 22, 156–166 (2008).
Article CAS PubMed Google Scholar
Vilardaga, J. P. et al. Molecular mechanisms of PTH/PTHrP class B GPCR signaling and pharmacological implications. Endocr. Rev. 44, 474–491 (2023).
Okazaki, M. et al. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc. Natl Acad. Sci. USA 105, 16525–16530 (2008).
Article CAS PubMed PubMed Central Google Scholar
Ferrandon, S. et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat. Chem. Biol. 5, 734–742 (2009).
Article CAS PubMed PubMed Central Google Scholar
Peña, K. A. Endosomal parathyroid hormone receptor signaling. Am. J. Physiol. Cell Physiol. 323, C783–c790 (2022).
Article PubMed PubMed Central Google Scholar
Feinstein, T. N. et al. Retromer terminates the generation of cAMP by internalized PTH receptors. Nat. Chem. Biol. 7, 278–284 (2011).
Article CAS PubMed PubMed Central Google Scholar
White, A. D. et al. Ca2+ allostery in PTH-receptor signaling. Proc. Natl Acad. Sci. USA 116, 3294–3299 (2019).
Article CAS PubMed PubMed Central Google Scholar
Hattersley, G., Dean, T., Corbin, B. A., Bahar, H. & Gardella, T. J. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157, 141–149 (2016).
Article CAS PubMed Google Scholar
Sato, T. et al. Comparable initial engagement of intracellular signaling pathways by parathyroid hormone receptor ligands teriparatide, abaloparatide, and long-acting PTH. JBMR Plus 5, e10441 (2021).
Article CAS PubMed PubMed Central Google Scholar
Wein, M. N. & Kronenberg, H. M. Regulation of bone remodeling by parathyroid hormone. Cold Spring Harb. Perspect. Med. 8, a031237 (2018).
Article PubMed PubMed Central Google Scholar
Wein, M. N., Foretz, M., Fisher, D. E., Xavier, R. J. & Kronenberg, H. M. Salt-inducible kinases: physiology, regulation by cAMP, and therapeutic potential. Trends Endocrinol. Metab. 29, 723–735 (2018).
Article CAS PubMed PubMed Central Google Scholar
Wan, M. et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 22, 2968–2979 (2008).
Article CAS PubMed PubMed Central Google Scholar
Jilka, R. L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40, 1434–1446 (2007).
Article CAS PubMed PubMed Central Google Scholar
Bellido, T., Saini, V. & Divieti Pajevic, P. Effects of PTH on osteocyte function. Bone 54, 250–257 (2013).
Article CAS PubMed Google Scholar
Pacifici, R. Role of T cells in the modulation of PTH action: physiological and clinical significance. Endocrine 44, 576–582 (2013).
Article CAS PubMed Google Scholar
Pacifici, R. T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone. Ann. N. Y. Acad. Sci. 1364, 11–24 (2016).
Article CAS PubMed Google Scholar
Alekos, N. S. et al. Mitochondrial β-oxidation of adipose-derived fatty acids by osteoblasts fuels parathyroid hormone-induced bone formation. JCI Insight 8, e165604 (2023).
Article PubMed PubMed Central Google Scholar
Delgado-Calle, J. & Bellido, T. The osteocyte as a signaling cell. Physiol. Rev. 102, 379–410 (2022).
Article CAS PubMed Google Scholar
Tu, X. et al. Osteocytic PTH receptor is required for bone anabolism induced by intermittent PTH administration, but is dispensable for bone resorption and the loss of bone induced by chronic PTH elevation. J. Bone Miner. Res. 28, S233 (2013).
留言 (0)